Billy Tauzin’s 2008 compensation from PhRMA was $4,476,157

Billy Tauzin announced today that he will be stepping down as President and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA) at the end of June 2010.

PhRMA’s 990 Tax Return Form, Schedule J-1 shows the amount Tauzin was compensated in 2008:

Base compensation: $2,055,445
Bonus & incentive compensation: $692,875
Other reportable compensation: $159,412
Deferred compensation: $1,556,960
Nontaxable benefits: $11,465

Total: $4,476,157
Continue Reading

Uncategorized

Rethinking compulsory licensing for export: WTO members hold informal consultations on Paragraph 6 implementation

Friday, 12 February 2010

Around 100 Members of the World Trade Organization attended informal consultations today in Room E (a mainstay of the green room consultations) to discuss the implementation of Paragraph 6 mechanism which was created to be an “an expeditious solution” for “WTO members with insufficient or no manufacturing capacities in the pharmaceutical sector” that faced difficulties in in “making effective use of compulsory licensing under the TRIPS Agreement”.

Continue Reading

Uncategorized

PCT Patent Filings per million residents

The use of the patent system is quite different from country to country. The following table provides the number of WIPO PCT patent filings, by country of origin, from January 2005 to November 2009, per million residents.* The source of the data on PCT filings is the February 2010 version of the WIPO Statistics Database. (WIPO notes the 2009 data are provisional and incomplete). The PCT counts are based on the international filing date and the country of residence of the first named applicant.

Continue Reading

Uncategorized
4

PhRMA’s grants to US organizations in 2008

In the United States, tax exempt non-profit organizations are subject some some requirements for financial disclosure via the IRS form 990, which is available to the public. The disclosure requirements cover most U.S. based trade associations, including the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade association for some 28 “member” companies.

Continue Reading

Uncategorized

WIPO Symposium on the Evolution of the Regulatory Framework of Test Data

As mentioned, before WIPO is holding a symposium on February 8, 2010 on the “Evolution of the Regulatory Framework of Test Data – From the Property of the Intellect to the Intellect of Property”. The symposium will be held from 9:30 AM to 5 PM in Room B of WIPO headquarters.

The program of the symposium can be found here: http://www.wipo.int/edocs/mdocs/mdocs/en/wipo_ip_lss1_ge_10/wipo_ip_lss1_ge_10_inf_1_prov.pdf

Continue Reading

Uncategorized
1

Deadlock at 14th session of the WIPO Standing Committee on the Law of Patents (SCP)

After a around 10 hours of informal consultations today, it appears that the 14th session of the WIPO Standing Committee on the Law of Patents (SCP) has not reached consensus on new items for the Committee’s consideration. From sources close to the negotiation, much of the wrangling dealt with whether to preserve the non-exhaustive nature of the list of issues identified at SCP 12 and SCP 13. Continue Reading

Uncategorized

Suggestions by Asian Like-Minded Countries on Future Work of the WIPO Standing Committee on the Law of Patents (SCP)

The members of the “Asian Like-Minded Countries” group are: India, Indonesia, Iran and Pakistan.


Agenda 8: Future Work

1. [Following a proposal by the Chair,] the Committee

(a) reaffirmed that the non-exhaustive list of issues identified at the twelfth session of the SCP held in June 2008, and updated at its 13 session, would remain open for further elaboration and discussion at its next session(1);

Continue Reading

Uncategorized

SCP 14: Draft text on Future Work

Around 4:20 PM CET, the following draft text was made available for for Member States’ consideration. Currently, the countries are in informals considering the following text.

Around 5:50 PM, a draft text entitled “Suggestion by Asian Like-Minded Countries” was made available.

Among the key amendments suggested was the following language:

“Comments of Member States and Observers would be reflected in annexures appended to the respective studies”

Continue Reading

Uncategorized